Market Overview

Barrington Research Reiterates Integra LifeSciences Outperform, $50 PT

Barrington Research reiterated its Integra LifeSciences (NASDAQ: IART) Outperform rating and $50 price target in a research report published today.

In the report, Barrington Research states, "We are reiterating our OUTPERFORM rating and $50 target following IART's Q4/11 results based on the organic and inorganic growth opportunities in each of IART's end markets."

Shares of Integra LifeSciences were trading at $31.77 at the time of posting, up 1.92% from Monday's market close.

Posted-In: integra lifesciencesAnalyst Color Price Target Reiteration Analyst Ratings

 

Most Popular

Related Articles (IART)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free